Key result
High-dose cyclophosphamide, cisplatin, and BCNU carry ~5% cardiac complication risk, predicted by age and prior radiation.
Why the study?
What is the incidence of cardiac toxicity in breast cancer patients treated with high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I)?
Population
443 breast cancer patients (stage II-III n=243, stage IV n=200)
Design
Cohort
Authors
Loading...
May warrant cardiac surveillance in older patients or those with prior radiation on STAMP-I; leaves open need for prospective validation of predictors.
Cohort (n=443)
What is the incidence of cardiac toxicity in breast cancer patients treated with high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I)?
The STAMP-I chemotherapy regimen for breast cancer is associated with a 5.1% incidence of cardiac complications, with higher risk in older patients and those with prior chest radiation.
Nieto et al. (2000) conducted a cohort in Breast cancer (n=443). High-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) with autologous stem cell support was evaluated on Incidence of cardiac complications (clinical and subclinical). High-dose cyclophosphamide, cisplatin, and BCNU for breast cancer had a 5.1% overall incidence of cardiac complications, with prior radiation and advanced age as independent predictors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: